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Hormonal contraception has been associated with a reduced risk of vaginal dysbiosis,
which in turn has been associated with reduced prevalence of sexually transmitted infec-
tions (STIs), including HIV. Vaginal rings are used or developed as delivery systems for con-
traceptive hormones and antimicrobial drugs for STI and HIV prevention or treatment. We
hypothesized that a contraceptive vaginal ring (CVR) containing oestrogen enhances a lac-
tobacilli-dominated vaginal microbial community despite biomass accumulation on the
CVR’s surface.
Methods
We enrolled 120 women for 12 weeks in an open-label NuvaRing® study at Rinda Ubuzima,
Kigali, Rwanda. Vaginal and ring microbiota were assessed at baseline and each ring
removal visit by Gram stain Nugent scoring (vaginal only), quantitative PCR for Lactobacil-
lus species, Gardnerella vaginalis and Atopobium vaginae, and fluorescent in situ hybridiza-
tion to visualize cell-adherent bacteria. Ring biomass was measured by crystal violet
staining.
Results
Bacterial vaginosis (BV) prevalence was 48% at baseline. The mean Nugent score
decreased significantly with ring use. The presence and mean log10 concentrations of Lacto-
bacillus species in vaginal secretions increased significantly whereas those of G. vaginalis
and presence of A. vaginae decreased significantly. Biomass accumulated on the CVRs
with a species composition mirroring the vaginal microbiota. This ring biomass composition
and optical density after crystal violet staining did not change significantly over time.
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Conclusions
NuvaRing® promoted lactobacilli-dominated vaginal microbial communities in a population
with high baseline BV prevalence despite the fact that biomass accumulated on the rings.
Introduction
The vaginal microbial community (VMC) of healthy women consists predominantly of Lacto-
bacillus spp [1,2]. Its diversity increases in the context of vaginal dysbiosis, which is most com-
monly consistent with the well-known clinical condition bacterial vaginosis (BV) [3,4].
Associations between the presence of lactobacilli-dominated VMC and lower prevalence of
sexually transmitted infections (STIs), including HIV, have been shown [5]. Similarly, vaginal
dysbiosis has been reported to be associated with the presence of STIs [6] and to increase the
risk of Chlamydia trachomatis, Neisseria gonorrhoea, Trichomonas vaginalis, Mycoplasma geni-
talium, human papillomavirus, herpes simplex virus type 2 (HSV-2) and HIV infection [7–13].
Lactobacilli ferment glucose into lactic acid, which results in an acidic vaginal environment.
This is considered to be key to rendering the vagina unfavourable for STI pathogens and
anaerobic bacteria associated with BV [14,15]. In addition, lactobacilli produce bacteriocins
and compete with STI pathogens for nutrients and vaginal surface epithelium to adhere to
[16]. Interventions aimed at restoring and enhancing a lactobacilli-dominated VMC and
reducing BV incidence may contribute to the global reduction of the STI and HIV burden.
Several studies have shown that women using hormonal contraception are less likely to
develop BV [17]. Oestrogen stimulates vaginal epithelial cells to produce glycogen, which is a
source of the cell-free glucose that lactobacilli ferment [18].
Although a lactobacilli-dominated VMC is associated with vaginal health, not all lactobacilli
are equally protective [16,19]. Lactobacillus crispatus, L. iners, L. jensenii, L. gasseri and L. vagi-
nalis are the most common lactobacilli species found in the vagina [1,16]. Their occurrence
varies according to exogenous and endogenous exposures such as age, sexual activity, vaginal
oestrogen levels, and menses [14]. L. crispatus and L. iners are most frequently detected. L. cris-
patus offers protection against vaginal dysbiosis and STIs, whereas L. iners, although present in
almost all women worldwide, has been associated with more frequent transition into a dysbio-
tic VMC [20,21] and correlates well with BV associated bacteria [22]. It still remains to be elu-
cidated to what extent L. gasseri, L. jensenii and L. vaginalis protect the vaginal environment.
Recently, BV has been associated with the presence of biofilm on vaginal epithelial cells
[23,24]. This phenomenon was originally observed by Amsel et al., who called the exfoliated
vaginal epithelial cells covered with bacteria”clue cells” [25]. Biofilm presence in the vagina has
since been confirmed using fluorescence in situ hybridization (FISH) techniques [23]. Studies
have also shown biofilms on vaginally inserted inert materials such as intra-uterine devices
and tampons [26–28], and more recently on vaginal rings [29–32].
Vaginal rings are currently available as contraceptive vaginal rings (CVRs), and are being
developed as delivery systems for antimicrobial drugs to prevent or treat STIs, including HIV,
(also named vaginal microbicides [33,34]) or for both hormones and antimicrobial drugs (also
named multipurpose vaginal rings [35,36]). CVRs such as the NuvaRing1 are typically worn
for three weeks followed by a one week break to allow for withdrawal bleeding. However, in
order for a vaginal ring to prevent HIV or other STIs, it should be worn continuously over an
extended period of time. As yet, not much is known about biomass development on vaginal
rings. We identified three studies: a small study used rings loaded with tenofovir in primates
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[29], another studied vaginal rings releasing antiretrovirals for HIV prevention [30], and one
reported biomass on vaginal rings delivering acyclovir for treatment and suppression of genital
HSV [31,32]. Biomass was not detected on a Nuvaring1 used for three weeks by one healthy
woman [37].
Overall, studies on the effect of potential vaginal ring biomass on the vaginal microbiota
and on the extent to which the local release of oestrogen and biomass accumulation influence
one another are lacking.
We have previously reported our findings regarding biomass deposition on the NuvaRing1
and its association with the status of the VMC. We also found that the concentration of Gard-
nerella vaginalis and Atopobium vaginae in the eluates of the vaginal ring fragments measured
by quantitative (q)PCR were positively associated with the density of the biomass on the CVR
[38].
In this study we longitudinally assessed the impact of NuvaRing1 use on the incidence of
BV by Nugent score and on selected vaginal bacterial species and studied the presence of bio-
film in the vagina and biomass on the ring in a population of Rwandan women with a high BV
prevalence. We hypothesized that CVR use would promote a lactobacilli-dominated VMC
even though biomass may accumulate on the CVRs.
Methods
Design
This study was an open-label single-centre cohort study evaluating the safety on the vaginal
microbiota of the NuvaRing1 (Organon, Oss, The Netherlands) in Rwandan women (Clini-
calTrials.gov, identifier NCT01796613)(S1 Protocol, S1 Checklist) [39]. The study was con-
ducted at the Rinda Ubuzima (RU) research centre in Kigali, Rwanda. HIV negative, non-
pregnant women were randomised, using allocation sequence and envelopes created at the
ITM, to an intermittent or continuous CVR use regimen. The randomisation allocation
sequence and Women in the intermittent use group had the ring inserted for three weeks, fol-
lowed by one week off; women in the continuous use group used the ring for three weeks, with
the next ring being inserted immediately after the previous one and no off period in between.
The women were followed for 12 weeks with study visits planned to coincide with times of
ring removal and insertion.
The study was reviewed and approved by the ethics committees of the Institute of Tropical
Medicine (ITM), Belgium; the University Hospital Antwerp, Belgium (approval number:
B300201316845); the University of Liverpool, UK; the Rwandan National Ethics Committee;
National Health Research Committee; and Ministry of Health. All study participants provided
written informed consent for participation in the study.
Investigational product
The NuvaRing1 releases etonogestrel and ethinylestradiol at an average of 0.120 mg and
0.015 mg, respectively, per 24 hours, over three weeks.
Study participants
We recruited healthy women who were not using a modern contraceptive method, and had
not been using one in the three months prior to screening. Women eligible for enrolment
were aged 18–35, currently not pregnant, sexually active, HIV negative, and not using antimi-
crobials [39].
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Clinical study
At baseline, blood was taken for HIV, HSV-2 and syphilis serology and urine for pregnancy
testing. The urine pregnancy testing was repeated at ring removal visits; no pregnancies were
detected during follow-up. Vaginal specimens were collected by a study physician at baseline
and ring removal visits. In continuous users, samples were taken before the next ring insertion.
Vaginal specimens were tested for Chlamydia trachomatis and Neisseria gonorrhoeae by PCR
at baseline, for Trichomonas vaginalis and Candida spp. by wet mount and for BV by Nugent
scoring of Gram stained slides at baseline and ring removal visits. We only employed validated
test kits, methods, and procedures. Diagnosed infections were treated according to national
guidelines, which meant that BV and candidiasis were only treated when symptomatic.
Laboratory procedures
Vaginal specimens. During each pelvic examination, vaginal fluid from the posterior for-
nix of the vaginal wall was collected using one cotton and two Copan flocked1 (Copan, Bre-
scia, Italy) swabs. The cotton swab was used to prepare a wet mount, which was read within 20
minutes, and subsequent Gram staining and Nugent scoring [40]. In addition, the cotton swab
was rolled onto a Superfrost Plus1 slide (Menzel-Gla¨ser, Braunschweig, Germany) for future
FISH analysis. The slides for Nugent scoring and FISH were heat-fixed. The Superfrost Plus1
slides were stored and shipped at room temperature to the ITM where they were re-fixed in
Carnoy solution (6:3:1, ethanol:chloroform:glacial acetic acid) for at least 12 hours. The Copan
flocked1 swabs were eluted by vortexing each swab for a minimum of 15 seconds in 1.2 mL
diluted phosphate buffered saline (dPBS) (pH 7.4–1:9, PBS:saline). The eluates were stored at
-80˚C until shipped frozen to the ITM for qPCR analysis.
The Superfrost Plus1 slides were examined using Peptide Nucleic Acid (PNA)-FISH
employing species-specific probes for Atopobium vaginae (AtoITM1) and Gardnerella vaginalis
(Gard162), and the broad-range BacUni-1 probe. Procedures and definitions of observations
are described elsewhere [41].
The total bacterial load in the vaginal specimens of Lactobacillus genus, L. crispatus, L. iners,
L. jensenii, L. gasseri, L. vaginalis, A. vaginae and G. vaginalis was determined by qPCR assays.
DNA was extracted from 250 μL of Copan1 flocked swabs ‘eluates using the magnetic bead
m2000 System DNA extraction kit on the Abbott m2000 automated platform (Abbott, Maid-
enhead, UK). The extraction program as customized by the manufacturer for DNA plasma
extraction was optimized by including a pre-extraction heating lysis step. qPCR was performed
for each bacterium species separately, as previously described [42].
Contraceptive vaginal rings. All used CVRs were collected by the study clinician and
immediately delivered to the onsite RU laboratory. The CVRs were cut into three identical
pieces using a ring template. One piece for PNA-FISH was stored in 3 mL Carnoy solution
between 2–8˚C; one piece for qPCR was kept in 3 mL dPBS at -80˚C; and the third piece was
submerged in 3 mL of glutaraldehyde, transferred after two weeks into 3 mL of formaldehyde
and stored at 2–8˚C, for crystal violet (CV) staining and scanning electron microscopy (SEM).
Pieces in dPBS were shipped under frozen condition, the others at ambient temperature to the
ITM. The ring pieces were processed and analysed as described elsewhere [38].
Sample size and power calculation
The study sample size calculation was based on the primary objective to assess the before-after
changes in the vaginal microbiota in both groups. To detect a change of 0.5 log10 in Lactobacil-
lus genus concentration, expressed as genome equivalents (geq) per ml of vaginal eluate, after
ring use within each randomization group with 95% power using a two-sided paired test with
Ring Plus Study: Vaginal microbial community and biofilm
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alpha = 5% and assuming a standard deviation of 1 log10, we required 52 women per group.
To correct for early withdrawals and women lost-to-follow up, we randomised 120 women (60
randomised to the intermittent regimen, and 60 to the continuous regimen) to ensure we had
104 women with primary endpoint data available.
Statistical analysis
Women in each treatment group were described with respect to baseline characteristics using
medians and interquartile ranges (IQRs) for continuous characteristics and counts and per-
centages for categorical characteristics. The proportion of ring-use emergent BV cases (i.e.,
women with Nugent score 0–3 at enrolment and at least one Nugent score of 7–10 at any visit
after first ring insertion) were compared using Fisher’s exact test.
Bacteria present in the vaginal microbiota and/or in the ring biomass as determined by
qPCR were expressed categorically as present or absent and as log10-transformed concentra-
tions in geq/mL of vaginal swab eluate. Samples in which none of the assessed species were
detected were excluded and considered inadequate (inhibition or insufficient sample material).
A composite qPCR vaginal health score was calculated as log10 Lactobacillus genus concentra-
tion -log10 (G. vaginalis+A. vaginae concentrations) [43].
The evolutions of vaginal microbiota and ring biomass compositions by qPCR over time
were modelled with linear or logistic mixed effects models using one different variance param-
eter per random effect with covariance 0. These models include fixed effects for time and the
interaction between time and intervention group and random effects for intercept and time.
For ring biomass data, baseline measurements were not applicable by definition. We compared
the use of time as a categorical variable to a linear time effect (estimating difference in outcome
between consecutive visits) and a binary time effect (estimating difference in outcome between
post-baseline and baseline) and selected the most appropriate one for each model.
Time evolution of log10 geq of species/mL of vaginal swab eluate were only modelled if the
species were present in at least 75% of samples for at least 50% of women.
Effects of intermittent versus continuous use were tested as differences in slopes in the
models at the 5% level (two-sided).
We also planned to adjust for BV treatment within the last three weeks. However the major-
ity of women with BV by Nugent were asymptomatic and did not require treatment according
to the Rwandan national guidelines. Only four women received metronidazole treatment
within the three weeks of specimen collection. A pilot analysis with adjustment provided simi-
lar results as the analyses without adjustment, and it was therefore decided not to proceed with
the adjustment for BV treatment.
Analyses were performed using Stata, version 14.0 (StataCorp, College Station, TX, USA).
Results
Characteristics of the study population
The study was conducted from June 2013 until January 2014. All 120 study participants, 60
intermittent and 60 continuous users, provided demographic and microbiological data at base-
line, and 119 participants completed the study. One participant from the continuous use
group discontinued prematurely and contributed only one cycle of CVR use (Fig 1). The
median age was 28, about two thirds of women ever used a hormonal method of contracep-
tion, and almost all had at least one child (Table 1).
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High prevalence of BV and BV vaginal biofilms at baseline
A total of 119/120 vaginal slides collected at baseline for Nugent scoring were interpretable:
40% showed a normal vaginal microbiota; 12% an intermediate microbiota; and 48% BV
(Table 1). Two women with BV had clinical symptoms and were treated.
The FISH analysis provided 100/120 interpretable results at baseline; 39% of the vaginal slides
showed planktonic/dispersed bacteria only (morphologically indistinguishable, planktonic bacte-
ria are free-living whereas dispersed bacteria are dispersed from a biofilm) and 17 of them did not
show any G. vaginalis and A. vaginae. The other 61% of vaginal slides showed a biofilm and on
nine of these slides no G. vaginalis and A. vaginae was detected as part of the biofilm. Planktonic/
dispersed G. vaginalis was observed in 79% of the interpretable slides, of which 65% (51/79)
included cell-adherent G. vaginalis in a biofilm structure. A total of 52% (52/100) of vaginal slides
showed biofilm containing G. vaginalis. Planktonic/dispersed A. vaginae was observed in 55% of
the interpretable slides, of which 49% (27/55) were cell-adherent. Finally, 28% (28/100) showed
biofilm structures containing A. vaginae and all of them also contained G. vaginalis.
Of the 120 vaginal specimens analysed by qPCR, one could not be interpreted. Lactobacillus
genus was detected in the majority (92%) of the vaginal specimens: L. iners was most fre-
quently (75%) detected, followed by L. vaginalis (30%), L. crispatus (14%), L. gasseri (15%), and
L. jensenii (13%). The presence of G. vaginalis (84%) and A. vaginae (61%) was also high.
High incidence and persistence of BV
Of the 48 women with a Nugent score of 0–3 at baseline, 17% (4/24) of the intermittent and
33% (8/24) of the continuous users developed a Nugent score of 7–10 at least once during ring
use; the difference between the two study groups was not significant. BV persisted or recurred
during the study in 67% (38/57) of the women who had BV at baseline.
Over the course of the study, six women were treated with metronidazole: three for BV and
three for trichomoniasis. At the final visit one extra woman was treated for BV and four for
trichomoniasis.
Lactobacilli presence and concentrations increased during ring use but the
presence of a polymicrobial biofilm remained
The odds of presence of lactobacilli in vaginal secretions increased significantly over time
within each group (intermittent: P = 0.031, continuous: P = 0.041) with no significant
Fig 1. Participant flow. N = number of participants,  1 discontinued after one cycle of vaginal ring use.
https://doi.org/10.1371/journal.pone.0201003.g001
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Table 1. Baseline characteristics, reproductive tract and sexually transmitted infections of all randomised participants who used at least one contraceptive vaginal
ring.
Intermittent Use Continuous Use Total
N 60 60 120
Age—(year): median (IQR) 28 (25.5, 31) 28.5 (26, 32) 28 (26, 31.5)
Highest Level of Education—n (%)
No schooling 9 (15) 6 (10) 15 (13)
Primary school not completed 15 (25) 21 (35) 36 (30)
Primary school completed 24 (40) 20 (33) 44 (37)
Secondary school not completed 8 (13) 9 (15) 17 (14)
Secondary school completed 2 (3) 2 (3) 4 (3)
More than secondary school 2 (3) 2 (3) 4 (3)
Marital Status/Home Situation—n (%)
Married 37 (62) 36 (60) 73 (61)
Living together 16 (27) 16 (27) 32 (27)
Regular partner, but not living together 7 (12) 8 (13) 15 (13)
Contraception History—n (%)
None 19 (32) 22 (37) 41 (34)
Any modern method 41 (68) 38 (63) 79 (66)
Hormonal
Injectables1- n (%) 32 (53) 27 (45) 59 (49)
Pills1,3- n (%) 11 (18) 18 (30) 29 (24)
IUD1- n (%) 1 (2) 0 (0) 1 (1)
Pregnancies—n (%)
0 2 (3) 3 (5) 5 (4)
1 12 (20) 10 (17) 22 (18)
2 22 (37) 17 (28) 39 (33)
3 or more 24 (40) 30 (50) 54 (45)
Any vaginal deliveries—n (%) 55 (92) 51 (85) 106 (88)
Any C-sections—n (%) 6 (10) 11 (18) 17 (14)
C. trachomatis PCR—positive n (%) 4 (7) 6 (10) 10 (8)
N. gonorrhoea PCR—positive n (%) 2 (3) 5 (8) 7 (6)
HIV serology—positive n (%) 0 (0) 0 (0) 0 (0)
HSV-2 serology—positive n (%) 21 (35) 26 (43) 47 (39)
Syphilis serology—positive n (%) 3 (5) 3 (5) 6 (5)
Wet Mount:
Candida sp- positive n (%) 2 (3) 4 (7) 6 (5)
T. vaginalis—positive n (%) 5 (8) 4 (7) 9 (8)
Clue Cells—n (%)
None 44 (73) 37 (62) 81 (68)
<20% 9 (15) 16 (27) 25 (21)
> = 20% 7 (12) 7 (12) 14 (12)
Nugent score2- n (%)
0–3 24 (40) 24 (41) 48 (40)
4–6 7 (12) 7 (12) 14 (12)
7–10 29 (48) 28 (47) 57 (48)
IQR: Interquartile Range
1More than one answer possible
21 Missing/unreadable
3combined oral contraceptive pills
 None of the participants had ever used a vaginal ring for contraception prior to enrolment in the study
https://doi.org/10.1371/journal.pone.0201003.t001
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difference between the two study groups (Table 2, S1 Fig). The increases were significant over
time for L. crispatus, L. jensenii and L. vaginalis (P value range 0.003–0.033) but not for L. gas-
seri. The increase of the odds of presence over time of L. iners was significant for the continu-
ous use group (P = 0.027) and borderline significant for the intermittent use group (P = 0.051).
The odds of G. vaginalis and A. vaginae presence decreased significantly over time within each
group (G. vaginalis intermittent: P = 0.012, continuous: P = 0.004; A vaginae both groups:
P = 0.001), with no significant difference between the groups.
Lactobacillus genus (96.7%), L. iners (75.0%) and G. vaginalis (70.0%) were persistently
present in the vaginal microbiota of the majority of women. The mean log10 geq/ml vaginal
swab eluate of Lactobacillus genus and L. iners increased significantly (Lactobacillus genus both
groups: P<0.001; L. iners intermittent: P = 0.013, continuous: P = 0.003), whereas that of G.
vaginalis decreased significantly (both groups: P<0.001) over time (Table 3, S2 Fig).
The mean composite qPCR vaginal health scores were significantly higher at the end of the
study compared to the baseline values in both groups (Table 3). This effect did not significantly
differ between the two groups.
The mean Nugent score decreased significantly over time (both groups: P<0.001) and did
not differ significantly between intermittent and continuous users (Table 3 and Fig 2).
On average, the vaginal Nugent and composite qPCR vaginal health scores decreased and
increased, respectively, after use of the first CVR and remained stable thereafter as shown in
Fig 2.





Difference in time evolution between groups
OR (95% CI) P-value OR (95% CI) P-value P-value Time effect
Vaginal specimen
Lactobacillus genus 5.7 (1.2, 27.6) 0.031 4.4 (1.1, 18.0) 0.041 0.782 binary
L. crispatus 7.3 (1.5, 33.6) 0.014 4.5 (1.1, 17.5) 0.033 0.566 binary
L. iners 8.4 (1.0, 71.5) 0.051 13.1 (1.3, 128.3) 0.027 0.389 linear
L. jensenii 1.7 (1.1, 2.6) 0.022 1.8 (1.1, 2.8) 0.021 0.873 linear
L. gasseri 0.7 (0.3, 1.5) 0.363 1.1 (0.6, 2.0) 0.695 0.217 linear
L. vaginalis 2.2 (1.3, 3.8) 0.003 2.4 (1.4, 4.3) 0.003 0.742 linear
G. vaginalis 0.3 (0.1, 0.7) 0.012 0.2 (0.1, 0.6) 0.004 0.769 binary
A. vaginae 0.2 (0.1, 0.5) 0.001 0.2 (0.1, 0.6) 0.001 0.745 binary
G. vaginalis cell-attached 0.6 (0.4, 0.9) 0.015 0.5 (0.3, 0.8) 0.001 0.454 linear
G. vaginalisplanktonic/dispersed 0.6 (0.5, 0.8) 0.001 0.6 (0.5, 0.8) 0.001 0.815 linear
A. vaginae cell-attached1 1.3 (0.6, 2.8) 0.572 0.5 (0.2, 1.2) 0.126 0.069 binary
A. vaginae planktonic/dispersed 0.6 (0.2, 1.2) 0.149 0.2 (0.1, 0.5) <0.001 0.052 binary
Contraceptive vaginal ring
Lactobacillus genus 1.3 (0.7, 2.2) 0.408 1.3 (0.8, 2.3) 0.310 0.874 linear
G. vaginalis 0.6 (0.3, 1.3) 0.169 1.1 (0.6, 2.2) 0.776 0.235 linear
A. vaginae 0.8 (0.4, 1.3) 0.307 0.8 (0.5, 1.2) 0.266 0.996 linear
1All, except one, were accompanied by cell-attached G. vaginalis
Note.-The qPCR results were expressed categorically as present or absent. The presence of species was modelled using mixed-effects logistic regression models and
results were expressed as odds ratio (OR) of presence with 95% confidence interval (CI). When the model includes a binary time effect, the odds ratio is the odds of
presence post-baseline divided by the odds of presence at baseline. When the model includes a linear time effect, the odds ratio is the odds of presence at a certain visit
divided by the odds of presence at the previous visit.
The use of time as a categorical variable to a linear time effect and a binary time effect were compared and the most appropriate one was selected.
https://doi.org/10.1371/journal.pone.0201003.t002
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The odds of vaginal biofilms comprising of cell-attached and dispersed G. vaginalis as iden-
tified using PNA-FISH decreased significantly over time in both study groups (cell-attached,
intermittent: P = 0.015, cell-attached, continuous and planktonic/dispersed, both groups
P = 0.001). The odds of presence of planktonic/dispersed A. vaginae significantly decreased in
the continuous users only (P<0.001). The presence of biofilm containing A. vaginae, identified
by PNA-FISH as attached to vaginal epithelial cells, did not significantly change over time
(Table 2, S3 Fig). All vaginal biofilms containing A. vaginae, except one, contained G. vaginalis
as well, but not vice versa.
Biomass consisting of epithelial and bacterial cells accumulated on the
CVR and its composition did not change over time
An adherent biomass was detected on all 415 collected CVRs with a mean optical density after
CV staining of 3.35 (range 0.132–3.91). The mean biomass density did not evolve significantly
over time in any one group neither did it significantly differ between the groups (Table 3).
Of the 415 collected CVRs, two CVR pieces for qPCR were missing. Bacteria were amplified
from all 413 CVRs: 93% contained Lactobacillus genus, 57% G. vaginalis and 37% A. vaginae.
Over the course of the study, the odds of presence of Lactobacillus genus, G. vaginalis and A.
vaginae on the CVRs did not change significantly for either group (Table 2). However, the
mean log10 geq/ml vaginal swab eluate of G. vaginalis decreased significantly in the intermit-
tent (P = 0.024) and not in the continuous users (Table 3).
Applying the composite qPCR vaginal health score to the rings, a borderline significant
increase of the score was observed for the CVRs used intermittently (P = 0.050) but not for
Table 3. Longitudinal analysis of qPCR concentrations (log10 (geq)/mL of vaginal swab eluate) and Nugent scores in the Vagina and of qPCR concentrations (log10
geq/mL of vaginal ring eluate) and density of contraceptive vaginal ring biomasses in both study groups.




Difference in time evolution between groups
Estimate (95% CI) P-value Estimate (95% CI) P-value P-value Time effect
Vaginal specimen
Lactobacillus genus 0.8 (0.4, 1.1) <0.001 0.9 (0.5, 1.2) <0.001 0.671 binary
L. iners 0.7 (0.1, 1.2) 0.013 0.8 (0.3, 1.3) 0.003 0.755 binary
G. vaginalis -1.2 (-1.8, -0.6) <0.001 -1.3 (-1.9, -0.7) <0.001 0.786 binary
Composite qPCR vaginal health score 2.1 (1.3, 2.8) <0.001 2.3 (1.6, 3.0) <0.001 0.681 binary
Nugent score -1.6 (-2.3, -0.8) <0.001 -1.9 (-2.7, -1.2) <0.001 0.462 binary
Contraceptive vaginal ring
Lactobacillus genus -0.0 (-0.2, 0.1) 0.826 -0.0 (-0.2, 0.1) 0.657 0.868 linear
G. vaginalis -0.3 (-0.5, -0.0) 0.024 —0.1 (-0.3, 0.1) 0.433 0.263 linear
A. vaginae -0.1 (-0.4,0.1) 0.274 -0.2 (-0.4,0.0) 0.127 0.768 linear
Composite qPCR vaginal health score 0.3 (0.0, 0.6) 0.050 0.1 (-0.2, 0.4) 0.610 0.281 linear
Density 0.0 (-0.0, 0.1) 0.294 0.0 (-0.1, 0.1) 0.923 0.410 linear
Note.-The log10 concentrations (expressed in geq/mL vaginal swab eluate) of species that were persistently present in the vaginal microbiota, Nugent scores, vaginal and
ring biomass composite qPCR vaginal health scores, and ring biomass densities were modelled with mixed-effects linear regression models. For ring biomass data
baseline measurements were not applicable. Results were expressed as estimates (E) of change in mean log10 geq/mL vaginal swab eluate, in mean composite qPCR
vaginal health score, in mean Nugent score or in mean biomass density with 95% confidence intervals (CI). When the model includes a binary time effect, E is the mean
difference between post-baseline and baseline. When the model includes a linear time effect, E is the mean difference between two consecutive visits.
Effects of intermittent versus continuous use were tested as differences in slope in the models at the 5% level (two-sided).
Composite qPCR vaginal health scores were calculated as log10 (Lactobacillus genus)-log10 (G. vaginalis+ A. vaginae).
https://doi.org/10.1371/journal.pone.0201003.t003
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those used continuously. However, the difference between the two groups was not significant
(Table 3). The composite qPCR vaginal health scores of the CVRs and vaginal specimens were
concordant and evolved similarly.
SEM revealed that observed biomasses on the CVRs were composed of accumulated vaginal
epithelial cells either covered by loose structures of scattered elongated bacteria with a mor-
phology compatible with lactobacilli (Fig 3 pictures 1a-3a), or by dense structures compatible
with a biofilm structure of coccobacilli type (Fig 3 pictures 1b-3b).
Fig 2. Evolution over time of the mean vaginal Nugent score, the mean composite qPCR vaginal health score of
vaginal specimens, and the mean composite qPCR vaginal health score of contraceptive vaginal ring biomass. The
Y axis is a score from 0 to 10 for both the Nugent and the composite qPCR vaginal health score. RSV1: first ring
removal visit; RSV2: second ring removal visit; LRV: last ring removal visit ____: mean Nugent score _ _ _: mean
composite qPCR vaginal health score of the vaginal specimens . . .. . .: mean composite qPCR vaginal health score of
the contraceptive vaginal rings The composite qPCR vaginal health score is calculated as log10 (Lactobacillus spp.)-log10
(G. vaginalis+ A. vaginae).
https://doi.org/10.1371/journal.pone.0201003.g002
Fig 3. Scanning electron microscope observation of the biomass accumulated on contraceptive vaginal rings used for three weeks. Pictures 1a-3a: The
contraceptive vaginal ring was used by a woman with a Nugent score of 10 and with presence of Lactobacillus iners, Gardnerella vaginalis and Atopobium
vaginae as measured by qPCR. A vaginal biofilm consisting of Gardnerella vaginalis and Atopobium vaginae was identified using fluorescence in situ
hybridization. On the ring Lactobacillus species, Gardnerella vaginalis and Atopobium vaginae were detected using qPCR, the crystal violet optical density was
3.7555 Pictures 1b-3b: Biomass on a contraceptive vaginal ring after use by a woman with a Nugent score of 0 and presence of Lactobacillus iners only. No
biofilm was visualized using fluorescence in situ hybridization. On the ring Lactobacillus species was detected using qPCR, the crystal violet optical density was
3.7225.
https://doi.org/10.1371/journal.pone.0201003.g003
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The biomass on the CVR mirrored the vaginal microbiota
Four hundred seven CVR and vaginal specimen pairs were obtained, concordance as mea-
sured by qPCR (presence/absence) was observed in 94% of the pairs for Lactobacillus genus,
81% for G. vaginalis, and 88% for A. vaginae. Overall, the mean bacterial geq/mL vaginal ring
eluate detected on the CVRs were 0.5 to 1.1 log10 lower compared to the mean geq/mL vaginal
swab eluate in the vaginal secretions.
Fig 4 shows the evolution over time of the mean CVR biomass density using CV staining.
Women with a BV Nugent score of 7–10 developed the densest CVR biomass with a mean
optical density range of 3.5–3.6. Women with a normal Nugent score developed significantly
less CVR biomass and the optical density fluctuated between 3.1 and 3.3. The largest fluctua-
tion of the CVR biomasses optical density from 3.3 up to 3.6 was observed in women with an
intermediate Nugent score of 4–6 (Fig 4).
Discussion
We demonstrated that NuvaRing1 use in a population with a high BV prevalence improves
the vaginal microbiota over time. This observation was made independently of intermittent or
continuous ring use regimen, and was defined by a decrease in mean Nugent scores and an
Fig 4. Evolution over time of the density of contraceptive vaginal ring biomass according to the normal, intermediate
and BV vaginal microbiome as determined by Nugent scoring. The Y axis is the optical density of the crystal violet
measurements of the contraceptive vaginal rings. RSV1: first ring removal visit; RSV2: second ring removal visit; LRV: last
ring removal visit ____: mean optical densities of ring’s biomass collected from women with a normal vaginal microbiota
according to the Nugent score (0–3) _ _ _: mean optical densities of ring’s biomass collected from women with an
intermediate vaginal microbiota according to the Nugent score (4–6) . . .. . .: mean optical densities of ring’s biomass
collected from women with bacterial vaginosis according to the Nugent score (7–10).
https://doi.org/10.1371/journal.pone.0201003.g004
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increase in mean composite qPCR vaginal health scores (confirming the concurrent increase
of lactobacilli and decrease of G. vaginalis) in both study groups. The composite qPCR vaginal
health score evolution over time predicts whether the vaginal microbiota evolves towards a lac-
tobacilli-dominated vaginal microbiota (increasing scores) or towards a dysbiosis (decreasing
scores).
Furthermore, after the use of three CVRs, fewer women had a BV-associated vaginal bio-
film containing G. vaginalis. However, we did not observe such a reduction in women who
had a biofilm that also contained A. vaginae. Our findings agree with previous studies showing
a favourable effect of CVRs on the vaginal microbiota [44–46], and are in line with earlier
observations that the use of hormonal contraceptives, whatever their mode of administration,
reduces the occurrence of BV [47,48]. These promising observations should be used to encour-
age the development of multipurpose interventions for the prevention of STIs and HIV in
combination with pregnancy prevention.
Biomass was detected on all CVRs after having been inserted for three weeks, but biomass
densities remained stable over time, independent of the CVR regimen used. The mean log10
concentrations (expressed in geq/mL vaginal ring eluate) of individual bacteria present in the
ring biomasses did not significantly change over the course of the study either. A borderline
increase of the mean composite qPCR vaginal health score, explained by the reduction over
time of the mean G. vaginalis concentration, was observed in the intermittent users. However,
the increase was minor and may be of no importance. The significant decrease of the mean
vaginal Nugent score was achieved after the first CVR use where after the Nugent score stabi-
lized. We also observed that the biomass on the CVR was associated with the vaginal Nugent
score. Both observations explain the limited variation in biomass density over time. Details on
the association of CVR biomass with vaginal Nugent score, dysbiosis and biofilm are presented
elsewhere [38].
All cases, except for one, of vaginal biofilms including A. vaginae also included G. vaginalis,
as observed by FISH analysis. The proportion of women with vaginal biofilms containing G.
vaginalis decreased over time, but we could not show this for vaginal biofilms containing both
G. vaginalis and A. vaginae. The presence of multiple bacterial species may strengthen the bio-
film by specific multispecies interactions and gene regulations [49]. We postulate that, even
though the exogenous oestrogen delivered by the CVR directly into the vagina increases the
concentration of lactobacilli, the metabolites and bacteriocins produced by these lactobacilli
are ineffective against the presence of a polymicrobial biofilm. Studies have indeed demon-
strated that the robustness of biofilms increases with the diversity of its constituents [50].
However, we used FISH probes for G. vaginalis, A. vaginae, and total bacteria only and it is
therefore possible that the biofilms containing G. vaginalis and not A. vaginae were polymicro-
bial nonetheless.
The quantity of biomass on the CVR was estimated using optical density measurement
after CV staining. Unfortunately, CV also stains vaginal epithelial cells. We are therefore cau-
tious in describing all biomass on the rings as biofilm. We hypothesize that vaginal epithelial
cells play a major role in the attachment of the biomass on the vaginal ring and form a sub-
strate layer for the vaginal microorganisms. Macromolecules, bacteria and tissue cells compete
for space on the vaginal ring surface. It might be that epithelial cells adhere more rapidly to the
ring surface than bacteria [51]. qPCR performed on the biomass revealed that for the majority
of the participants the bacteria present on the rings were also present in their vaginal speci-
mens. We did not determine whether the bacteria embedded in the biomass were alive, but in
a study with Nesterone1/ ethinyl-estradiol CVRs used for up to one year, bacteria from the
rings were grown, confirming their viability. The authors also reported a high level of vaginal-
CVR agreement for Lactobacillus spp. and G. vaginalis [45].
Ring Plus Study: Vaginal microbial community and biofilm
PLOS ONE | https://doi.org/10.1371/journal.pone.0201003 July 23, 2018 12 / 17
Our continuous use regimen will most likely not reflect the way vaginal microbicides or
multipurpose rings will be used in the future. The active product loadings in the NuvaRing1 is
licensed for three weeks of use followed by a ring-free week, and off-label extended use may
have increased the risk of unintended pregnancies. Our design of continuous use mimicked
uninterrupted ring presence in the vagina for 12 weeks. However, individual CVRs were used
for a maximum of three weeks in both regimens, which limited our ability to study biomass
accumulation over extended periods of time.
We limited our study to the investigation of bacteria associated with vaginal health (several
Lactobacillus spp) and bacterial vaginosis (G. vaginalis and A.vaginae). We did not include bac-
teria such as staphylococci, streptococci and bacteria belonging to the Enterobacteriaceae fam-
ily that are associated with other types of VMC dysbiosis [52,53]. For now, we do not know
whether contraceptive vaginal rings modify other dysbiotic VMC as well and whether biomass
deposits on the CVRs also occur in the presence of other types of dysbiosis. We therefore rec-
ommend that future research in the context of vaginal health and vaginal ring use includes
other types of dysbiosis as well.
In conclusion, NuvaRing1 promoted lactobacilli-dominated VMC in a population with
high baseline BV prevalence despite the fact that biomass accumulated on the rings.
Supporting information
S1 Checklist. CONSORT checklist.
(PDF)
S1 Protocol. Final approved protocol for “The Ring Plus project: Safety and acceptability
of vaginal rings that protect women from unintended pregnancy” version 2.0, 16 April
2013.
(PDF)
S1 Fig. Presence of Lactobacillus genus, G. vaginalis and A. vaginae in the vagina of the par-
ticipants over the course of the study. The bar graphs present proportions of women with
Lactobacillus genus, G. vaginalis, A. vaginae absent and present. The abbreviations RSV1,
RSV2, RSV3 and LRV refer to the first ring removal visit, the second ring removal visit, the
third ring removal visit, and the last ring removal visit, respectively.
(TIF)
S2 Fig. Concentration of Lactobacillus genus, G. vaginalis and A. vaginae in the vagina of
the participants over the course of the study. The boxplots depict the median (white line),
25th and 75th percentiles (box) of the mean log10 concentrations (expressed in genome equiv-
alents/mL of vaginal swab eluate) of Lactobacillus genus, G. vaginalis, A. vaginae in vaginal
swabs collected at baseline and the ring removal visits. The whiskers show the expected spread
of the data, based on the median and interquartile range. Points outside of this range are indi-
vidually indicated (possible outliers).
The abbreviations RSV1, RSV2, RSV3 and LRV refer to the first ring removal visit, the second
ring removal visit, the third ring removal visit, and the last ring removal visit, respectively.
(TIF)
S3 Fig. Presence of cell-adherent and dispersed/planktonic G. vaginalis and A. vaginae in
the vagina of the participants over the course of the study. The bar graphs present propor-
tions of women with cell-adherent G. vaginalis, dispersed/planktonic G. vaginalis, cell-adher-
ent A. vaginae, dispersed/planktonic A. vaginae absent and present. The abbreviations RSV1,
RSV2, RSV3 and LRV refer to the first ring removal visit, the second ring removal visit, the
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third ring removal visit, and the last ring removal visit, respectively.
(TIF)
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